Core Viewpoint - ADTRAN Holdings, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, following the disclosure of issues with its financial statements [1][2]. Financial Disclosure - On May 13, 2025, ADTRAN announced that its audited consolidated financial statements for the years ended December 31, 2024, and December 31, 2023, as well as its unaudited condensed financial statements for interim periods in 2024, should no longer be relied upon and would be restated [2]. - The company identified at least one additional material weakness in its internal control over financial reporting as of December 31, 2024 [2]. - Following this announcement, ADTRAN's stock price decreased by $0.41, or 4.79%, closing at $8.15 per share on May 14, 2025 [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of ADTRAN stockholders who may have suffered losses due to the company's financial disclosures [1][3].

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Compass owns ...

Core Insights - Iovance Biotherapeutics is under investigation for potential violations of federal securities laws and unlawful business practices [1] - The company reported a significant decline in first quarter 2025 product revenue, totaling $49.3 million, down from $73.7 million in the previous quarter [3] - Iovance has revised its full fiscal year 2025 revenue guidance from a range of $450 million-$475 million to $250 million-$300 million, representing a reduction of over 40% at the midpoint [3] - Following the announcement, Iovance's share price dropped by $1.42, or approximately 44%, closing at $1.75 on May 9, 2025 [3] Company Performance - The first quarter 2025 product revenue of $49.3 million indicates a significant decrease compared to the previous quarter's revenue of $73.7 million [3] - The revision of the full-year 2025 revenue guidance reflects challenges in the launch dynamics of the T cell immunotherapy, Amtagvi (lifileucel), which was launched in the U.S. in the first half of 2024 [3] Market Reaction - The announcement of the revenue decline and guidance revision led to a sharp decline in Iovance's stock price, falling from $3.17 to $1.75 within a day [3]

Core Viewpoint - Cleveland-Cliffs Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following disappointing financial results and operational changes [1][3]. Financial Performance - Cleveland-Cliffs reported a larger than expected adjusted loss for Q1 2025, with a year-over-year revenue decline of 11% to $4.63 billion [3]. - The company's share price fell from $8.49 on May 7, 2025, to $7.15 on May 8, 2025, a decline of $1.34 per share [3]. Operational Changes - The company plans to fully or partially idle six steel plants due to negative impacts from underperforming non-core assets and lower index prices from late 2024 and early 2025 [3]. - Cleveland-Cliffs is repositioning its portfolio away from non-core markets, including rail, high-carbon sheet, and specialty plate products, and is focusing on the automotive industry [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit related to misleading statements made during the company's initial public offering in September 2024 [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of individuals who purchased Zenas BioPharma securities during the specified class period [3]. - Allegations include that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [4]. - The deadline for shareholders to register for the class action is June 16, 2025, and there is no cost to participate [5]. Group 2: Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing the importance of responsible business practices [6]. - The firm seeks recovery for investors who suffered losses due to misleading statements that artificially inflated the company's stock [6].

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Compass Diversified Holdings (“Compass” or the “Company”) (NYSE:CODI). The investigation concerns whether Compass and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 7, 2025, after the markets closed, Compass filed a Form 8-K which stated that the Audit Committee of Board ...

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating potential misleading statements and failures to disclose material information by Compass Diversified Holdings, which may violate federal securities laws [1]. Company Overview - Compass Diversified Holdings owns and manages a diverse set of middle-market businesses, including Lugano Holdings, Inc., which specializes in luxury jewelry design, manufacturing, and marketing [2]. Recent Developments - On May 7, 2025, Compass issued a press release stating it would not rely on its financial statements for fiscal 2024 due to an ongoing internal investigation into Lugano, leading to a delay in filing its 1Q25 Form 10-Q [3]. - The investigation, conducted by outside counsel and a forensic accounting firm, has preliminarily identified irregularities in Lugano's financing, accounting, and inventory practices [3]. - Following the announcement, Lugano's founder and CEO resigned, and Compass's stock price plummeted by $10.70, or nearly 62%, closing at $6.55 on May 8, 2025, with unusually high trading volume [3].

Core Viewpoint - The Schall Law Firm is investigating Cytokinetics for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Cytokinetics issued false or misleading statements or failed to disclose important information to investors [2]. - A report from BioPharma Dive indicated that the FDA has delayed the approval decision for Cytokinetics' drug aficamten, which is intended for hypertrophic obstructive cardiomyopathy, to review the company's risk management plan [2]. - Following the news of the FDA's delay, Cytokinetics' shares dropped by over 12% during afternoon trading on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who have suffered losses are encouraged to contact the firm for a free discussion of their rights [3].

Core Viewpoint - Aldeyra Therapeutics, Inc. is under investigation for potential violations of federal securities laws following the failure of its lead drug candidate, reproxalap, to demonstrate efficacy in treating dry eye disease, leading to a significant stock price decline [1][4][5]. Company Overview - Aldeyra Therapeutics is a biotechnology company focused on developing therapies for immune-mediated and metabolic diseases, with reproxalap as its lead drug candidate aimed at treating dry eye disease [2]. Clinical Trial Results - The company announced success in its Phase III clinical trial for reproxalap, claiming the results were "uniquely supportive" and met FDA requirements for New Drug Application (NDA) resubmission [3]. - However, the trial ultimately failed to demonstrate the drug's efficacy, with methodological issues identified, including differences in baseline scores across treatment arms, which did not satisfy FDA standards [4]. Stock Market Reaction - Following the FDA's Complete Response Letter on April 3, 2025, which stated that the NDA failed to demonstrate efficacy, Aldeyra's stock plummeted nearly 75% in one trading day, dropping from a closing price of $5.33 on April 2, 2025 [5].